{
    "title": "115_s1115",
    "content": "The Act titled \"Making Pharmaceutical Markets More Competitive Act\" aims to improve access to generic drugs by removing regulatory barriers to competition. The Federal Food, Drug, and Cosmetic Act is amended to prioritize the review of new drug applications for drugs with limited approved alternatives or listed under section 506E, aiming to expedite the process within 240 days. The Secretary requires applicants to provide detailed information on manufacturing facilities and testing sites for drug applications listed under section 506E. Inspections may be expedited for establishments proposing to manufacture such drugs. The Secretary can prioritize the review of other applications as needed. The Secretary can prioritize the review of drug applications as needed and provide status updates to applicants. A list of expired patents and exclusivity periods for approved drugs will be published on the FDA website every 180 days. SEC. 102. REPORTING ON PENDING GENERIC DRUG APPLICATIONS, PRIORITY REVIEW APPLICATIONS, AND INSPECTIONS. The Secretary of Health and Human Services is required to post quarterly reports on the FDA website regarding the number of pending generic drug applications and priority review applications under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The Secretary of Health and Human Services must provide quarterly reports on the number of generic drug applications and priority review applications under section 505(j) of the Federal Food, Drug, and Cosmetic Act, including details on application withdrawals, approval times, priority reviews, and actions taken by the Secretary. Additionally, an annual report on priority review applications must be submitted to specific Senate committees. The Special Committee on Aging of the Senate and the Committee on Energy and Commerce of the House of Representatives must submit an annual report by March 31 each year. The report should include the number of applications under section 505(j) of the Federal Food, Drug, and Cosmetic Act that are subject to priority review and awaiting action by the applicant or the Secretary. The annual report must include the number of applications under section 505(j) of the Federal Food, Drug, and Cosmetic Act subject to priority review and approved by the Secretary, as well as the number of applications meeting specific criteria regarding approved drugs and drug shortages. The Secretary must annually report on the time taken to schedule and complete inspections of facilities for drug and device approvals under the Federal Food, Drug, and Cosmetic Act. The Secretary must report annually on the time taken for inspections of facilities for drug and device approvals under the Federal Food, Drug, and Cosmetic Act, including the average and median time for-cause inspections. SEC. 201. EXPEDITING GENERIC COMPETITION by amending Chapter V of the Federal Food, Drug, and Cosmetic Act to include a new section for expediting generic drug development. The Secretary can expedite the development and review of drug applications with certain criteria, and requests must be made before submission. The Secretary has the authority to expedite other applications as deemed appropriate. Additional communication measures will be taken to speed up the approval process for specified drugs. The application for drug approval involves holding meetings with the sponsor, providing timely advice, assigning a project lead for complex products, and involving senior managers. The drug approval process includes collaborative reviews with senior managers and experienced staff. Sponsors must report on the marketing of approved drugs one year after approval. SEC. 202. LIST OF GENERIC DRUGS WITH LIMITED COMPETITION. Chapter V of the Federal Food, Drug, and Cosmetic Act is amended to include a new section for drug listing. The holder of an approved drug application must notify the Secretary within 180 days of removing, withdrawing, or transferring the drug from interstate commerce. Compliance can be delayed if not practicable, but must be done as soon as possible. The Secretary will cross-reference information to avoid duplicate reporting. Manufacturers complying with section 506C(a) are deemed to comply with this section. The Secretary will maintain information on drugs with limited competition. The FDA is required to maintain and publish information on approved drug applications, particularly for drugs with three or fewer application holders. This information includes the drug name, holder of the approved application, marketing status, and whether the drug is for treatment purposes. Updates must be made every 180 days. The FDA is required to maintain and publish information on approved drug applications, particularly for drugs with three or fewer application holders. This includes details such as the drug name, holder of the approved application, marketing status, and whether the drug is for treatment purposes. The Secretary may choose not to make collected information publicly available if it could adversely affect public health. When the Secretary publishes the information, relevant Federal agencies are notified. SEC. 203. Suitability petitions must be responded to within 90 days of submission. The Secretary of Health and Human Services must report on pending petitions annually. SEC. 204. Inspections. Section 505(j) of the Federal Food, Drug, and Cosmetic Act is amended to require the Secretary to re-inspect an establishment or make a determination within 45 days if necessary changes have been made in response to feedback on a report. The Secretary must re-inspect an establishment or make a determination within 45 days in response to feedback on a report."
}